Effects of once-weekly subcutaneous semaglutide on coronary artery disease outcomes in patients with type 2 diabetes with or at high risk for cardiovascular disease: Insights from the SUSTAIN-6 trial

Ahmed A. Kolkailah, Ildiko Lingvay, Idit Dobrecky-Mery, Alona Aharonovich, Jens Peter David, Cecilie Holse, Søren Rasmussen, Darren K. McGuire

Research output: Contribution to journalLetterpeer-review

Original languageEnglish (US)
Pages (from-to)1117-1120
Number of pages4
JournalDiabetes, Obesity and Metabolism
Issue number4
StateAccepted/In press - 2022

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this